The demand for glucagon-like peptide-1 (GLP-1) medications like Wegovy, Ozempic, Zepbound, and Mounjaro has surged in recent years, driven by their effectiveness for weight loss, blood sugar control, and the reduction of major cardiovascular events
Discussion With the popularity of GLP-1 RA medications and challenges in access and insurance coverage, we will continue to monitor these prescribing and dispensing trends over time
Novo Nordisk also stated that it retains 60% of the cost and the other 40% goes to middlemen in the complex US health system
Both estimands were used for the primary treatment period analysis for primary and secondary endpoints, unless specified otherwise
Professional Medical Disclaimer This article is educational and does not constitute medical advice
You can request a consultation to explore whether this approach fits your needs.